Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease

Mathew Thomas; Erinn Downs Kelly; Jame Abraham; Megan Kruse

doi:10.1053/j.seminoncol.2019.03.002

Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease

Semin Oncol. 2019 Apr;46(2):121-132. doi: 10.1053/j.seminoncol.2019.03.002. Epub 2019 Jun 17.

Authors

Mathew Thomas¹, Erinn Downs Kelly², Jame Abraham¹, Megan Kruse³

Affiliations

¹ Division of Breast Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
² Division of Breast Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
³ Division of Breast Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: [email protected].

PMID: 31239068
DOI: 10.1053/j.seminoncol.2019.03.002

Abstract

Invasive lobular carcinoma (ILC) is the second most common type of invasive breast cancer after invasive ductal carcinoma (IDC). Invasive lobular carcinoma has unique clinical, pathologic, and radiographic features which suggest that it is a distinct clinical entity; however, it is treated with the same treatment paradigms as IDC. Information regarding the specific treatment of ILC, including response to standard therapy, is sparse. Neoadjuvant treatment considerations are of great importance in this space as ILC is often found at a locally advanced stage. In this review, we summarize the classic features of ILC and the available data regarding efficacy of both endocrine therapy and chemotherapy in curative treatment of breast cancer.

Publication types

Review

MeSH terms

Breast Neoplasms / diagnosis
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Carcinoma, Lobular / diagnosis
Carcinoma, Lobular / pathology
Carcinoma, Lobular / therapy*
Disease Management*
Female
Humans
Neoplasm Invasiveness / pathology
Neoplasm Staging